Vertex Pharmaceuticals (VRTX) Non-Current Assets (2009 - 2026)

Vertex Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $14.8 billion for Q1 2026.

• In Q1 2026, Non-Current Assets rose 14.62% year-over-year to $14.8 billion; the TTM figure through Mar 2026 stood at $57.1 billion (up 15.5% YoY), while the FY2025 annual figure was $14.4 billion, up 11.64% from the prior year.
• Non-Current Assets was $14.8 billion for Q1 2026 at Vertex Pharmaceuticals, up from $14.4 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $14.8 billion in Q1 2026 to a low of $3.9 billion in Q1 2022.
• Historically, Non-Current Assets has averaged $9.6 billion across 5 years, with a median of $10.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets grew 8.36% in 2022, then jumped 76.89% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $4.9 billion in 2022, then jumped by 74.65% to $8.6 billion in 2023, then soared by 50.67% to $12.9 billion in 2024, then grew by 11.64% to $14.4 billion in 2025, then climbed by 2.16% to $14.8 billion in 2026.
• The last three Non-Current Assets figures came in at $14.8 billion (Q1 2026), $14.4 billion (Q4 2025), and $14.3 billion (Q3 2025), per Business Quant data.